Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

Richard Steven Morris net worth and biography

Richard Morris Biography and Net Worth

CFO of Passage Bio

Mr. Richard Morris is the CFO of Passage Bio.

How do I contact Richard Steven Morris?: The corporate mailing address for Mr. Morris and other Passage Bio executives is TWO COMMERCE SQUARE 2001 MARKET STREET 28TH FLOOR, PHILADELPHIA PA, 19103. Passage Bio can also be reached via phone at 267-866-0311 and via email at [email protected]. Learn More on Richard Steven Morris' contact information.
Has Richard Steven Morris been buying or selling shares of Passage Bio?: Richard Steven Morris has not been actively trading shares of Passage Bio during the last ninety days. Most recently, on Friday, May 21st, Richard Steven Morris bought 2,171 shares of Passage Bio stock. The stock was acquired at an average cost of $13.82 per share, with a total value of $30,003.22. Learn More on Richard Steven Morris' trading history.
Are insiders buying or selling shares of Passage Bio?: During the last twelve months, Passage Bio insiders bought shares 1 times. They purchased a total of 617,382 shares worth more than $518,600.88. During the last twelve months, insiders at the sold shares 5 times. They sold a total of 34,426 shares worth more than $31,251.59. The most recent insider tranaction occured on February, 13th when CFO Kathleen Borthwick sold 1,470 shares worth more than $1,425.90. Insiders at Passage Bio own 12.4% of the company. Learn More about insider trades at Passage Bio.
Information on this page was last updated on 2/13/2024.

Richard Steven Morris Insider Trading History at Passage Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/21/2021	Buy	2,171	$13.82	$30,003.22

Richard Steven Morris Buying and Selling Activity at Passage Bio

Passage Bio Company Overview

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Today's Range

Now: $1.15

$1.12

$1.20

50 Day Range

MA: $1.37

$0.99

$1.73

2 Week Range

Now: $1.15

$0.58

$1.79

Volume

284,220 shs

Average Volume

156,408 shs

Market Capitalization

$70.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.3